{"schema_version":"secwatch.filing_event.v1","accession":"0001005286-23-000059","form_type":"8-K","ticker":"LFCR","cik":"0001005286","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.441348+00:00","generated_at":"2026-06-18T00:03:49.857847+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lifecore Q2 FY2023 net loss $12.4M; revenue down 11% to $38.8M; initiates strategic alternatives review","bullets":["Revenue $38.8M, down 11% YoY; net loss $12.4M vs net income $4.2M a year ago.","Adjusted EBITDA $(0.4)M compared to $8.2M; Lifecore segment EBITDA $3.0M vs $9.1M.","Board initiates strategic alternatives review; retains Morgan Stanley; contingent on lender forbearance.","Signed term sheet with existing customer for substantial expansion including up-front payments.","Development pipeline grew to 25 active projects; 3 projects received FDA approval, expanding commercial products to 29."],"urls":{"canonical":"https://secwatch.observer/filing/0001005286-23-000059","json":"https://secwatch.observer/filing/0001005286-23-000059.json","markdown":"https://secwatch.observer/filing/0001005286-23-000059.md","text":"https://secwatch.observer/filing/0001005286-23-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000059/0001005286-23-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000059/lndc-20230316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:03:49.857847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d74cd65ae67818948e0c1568b08e08659a679664","claim":"LIFECORE BIOMEDICAL, INC. DE reported the fiscal 2023 second quarter ended November 27, 2022 results: revenue $38.8 million, net income $(12.4) million, EPS $(0.42) per diluted share.","evidence_excerpt":"Foods assets are reflected as part of the Curation Foods segment in all periods presented within the Company’s financial statements reported herein. • Consolidated revenues of $38.8 million, a decrease of (10.7)% year-over-year. • Consolidated gross profit of $7.1 million, a decrease of $7.6 million, or 51.7% year-over-year, primarily due to a $5.0 million decline","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000059/0001005286-23-000059-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal 2023 second quarter ended November 27, 2022"},{"label":"Revenue","value":"$38.8 million"},{"label":"Net income","value":"$(12.4) million"},{"label":"EPS","value":"$(0.42) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}